

I. Table of contents

1. Summary ..... 1

2. Zusammenfassung ..... 3

3. Introduction ..... 5

3.1. The neural crest ..... 5

3.1.1. The development of the neural crest ..... 6

3.1.2. Molecular signaling cues during neural crest induction ..... 7

3.1.3. Molecular signaling cues during neural crest specification ..... 8

3.1.4. Molecular signaling cues during neural crest migration ..... 9

3.1.5. Molecular signaling cues during neural crest differentiation ..... 10

3.1.6. The cranial neural crest ..... 11

3.1.7. The cardiac neural crest ..... 13

3.1.8. The vagal and sacral neural crest ..... 13

3.1.9. The trunk neural crest ..... 14

3.1.10. Postmigratory neural crest cells ..... 18

3.2. Melanocyte biology ..... 20

3.2.1. Melanocyte development ..... 20

3.2.2. Microphthalmia-associated transcription factor (MITF) ..... 20

3.2.3. Melanogenesis ..... 21

3.2.4. Melanocyte stem cells ..... 23

3.3. Neurocristopathies ..... 26

3.3.1. Waardenburg syndrome ..... 26

3.3.2. Hirschsprung’s disease ..... 27

3.3.3. DiGeorge syndrome ..... 27

3.3.4. Giant congenital melanocytic nevus ..... 29

3.3.5. Neoplastic neurocristopathies ..... 29

3.4. Melanoma ..... 31

## Table of contents

3.4.1.	Epidemiology.....	31
3.4.2.	Melanoma risk factors .....	33
3.4.3	UV-induced pathogenesis.....	34
3.4.4	Pathohistologic classification and tumor staging of cutaneous melanoma .....	34
3.4.5.	Melanoma progression model.....	36
3.4.6.	Molecular pathomechanisms in cutaneous melanoma .....	38
3.4.7.	Mitogen-activated protein kinase signaling pathway in melanoma .....	40
3.4.8.	PI3K/AKT signaling pathway in melanoma.....	41
3.4.9.	Role of cell cycle regulators in melanoma .....	42
3.4.10.	Microphthalmia-associated transcription factor in melanoma.....	43
3.4.11.	Readoption of neural crest features in melanoma .....	44
3.4.12.	SOX10 in melanoma.....	44
3.4.13.	WNT signaling in melanoma .....	45
3.4.14.	TGF- $\beta$ signaling in melanoma .....	46
3.4.15.	NOTCH signaling in melanoma .....	47
3.4.16.	Role of enhancer of zeste homologue 2 in melanoma .....	49
3.4.17.	Melanoma stem cells and tumor heterogeneity.....	50
3.4.18.	EMT in melanoma .....	51
3.4.19.	Melanoma therapy.....	53
3.5.	NKAP.....	57
3.6.	Nuclear speckles.....	61
3.7.	RNA splicing and spliceosome assembly .....	62
4.	Goals of the thesis .....	65
5.	Preliminary investigations.....	67
6.	Results .....	69
6.1.1.	The neural crest-relevant transcriptional regulator NKAP plays a role in melanoma..	69
6.1.2.	NKAP is expressed in primary human melanoma cell cultures .....	71
6.1.3.	Decreased NKAP expression is linked to poor patient survival.....	73

6.1.4.	CRISPR-CAS9 and shRNA efficiently ablate NKAP expression.....	73
6.1.5.	Loss of NKAP affects cell adhesion <i>in vitro</i> .....	75
6.1.6.	NKAP deficiency increases invasiveness <i>in vitro</i> .....	75
6.1.7.	Stable NKAP depletion induces a G1/G0 cell cycle arrest <i>in vitro</i> .....	77
6.1.8.	Forced adhesion does not rescue the G1/G0 cell cycle arrest .....	77
6.1.9.	Cell intrinsic mechanisms induce the cell cycle arrest in NKAP depleted cells .....	78
6.1.10.	NKAP deficiency enhances metastasis formation <i>in vivo</i> .....	79
6.1.11.	NKAP associates with EMT, cell adhesion and cytoskeleton remodeling.....	81
6.1.12.	NKAP over expression in M018017 cells is weak .....	82
6.1.13.	NKAP over expression only partly rescues the NKAP depletion phenotype <i>in vivo</i> ...	83
6.1.14.	NKAP appears with a punctuated pattern within the nucleus .....	83
6.1.15.	NKAP localizes to the nuclear speckles .....	85
6.1.16.	NKAP interacts with nuclear speckle components.....	86
6.1.17.	CIR knockdown does not phenocopy NKAP depletion .....	87
6.1.18.	NKAP depletion reduces translational activity.....	89
6.1.19.	NKAP expression levels are tightly regulated to allow optimal transcriptional activity .....	89
6.1.20.	Reduced adhesion is a consequence of impaired protein synthesis.....	90
6.1.21.	Delayed replenishment of the surface proteome partly induces the cell cycle arrest...	91
6.2.	Contributions.....	93
7.	Discussion .....	95
7.1.1.	The neural crest associated factor NKAP plays a role in melanoma.....	95
7.1.2.	Functional manipulations were limited to the human melanoma cell culture M010817 .....	96
7.1.3.	NKAP localizes to nuclear speckles and interacts with RNA processing factors .....	96
7.1.4.	Aberrant NKAP expression leads to impaired translational activity.....	97
7.1.5.	RNAseq data reveal compensational adaptations in response to decreased adhesion..	99
7.1.6.	NKAP is not involved in alternative splicing .....	99

## Table of contents

7.1.7.	CIR ablation does not phenocopy NKAP deficiency .....	100
7.1.8.	Despite reduced proliferation <i>in vitro</i> , tumor growth of NKAP depleted cells is not affected <i>in vivo</i> .....	100
7.1.9.	NKAP depletion increases the metastatic behavior <i>in vivo</i> .....	101
7.1.10.	From neural crest stem cells to melanoma .....	102
7.1.11.	Conclusion .....	102
8.	Materials and methods .....	105
8.1.	<i>In vivo</i> analysis .....	105
8.1.1.	Xenograft experiments .....	105
8.1.2.	Quantitative analysis of lung metastases .....	105
8.2.	<i>In vitro</i> analysis .....	106
8.2.1.	Molecular cloning .....	106
8.2.2.	Cell culture .....	107
8.2.3.	NKAP gene silencing by RNA interference in human melanoma cell cultures .....	108
8.2.4.	CRISPR/CAS9-mediated NKAP knockout in human melanoma cell cultures .....	110
8.2.5.	Generation of stably expressing HA_NKAP_eGFP human melanoma cell cultures .....	111
8.2.6.	Proliferation assays and cell cycle analysis .....	112
8.2.7.	Adhesion assay .....	112
8.2.8.	Boyden chamber invasion assay .....	113
8.2.9.	Immunocytochemistry .....	113
8.2.10.	Protein isolation and immunoblot analysis .....	114
8.2.11.	RNA isolation and real-time quantitative PCR .....	115
8.2.12.	RNA sequencing and gene expression profiling .....	116
8.2.13.	Pull-down assays and mass spectrometry .....	117
8.2.14.	Translational activity assay .....	117
8.3.	<i>In silico</i> analysis .....	118
8.3.1.	TCGA analysis .....	118
8.3.2.	Statistical analysis .....	118

9. References ..... 119

10. Curriculum vitae..... 147

11. Acknowledgements ..... 153